Alterity Therapeutics (ATHE) Common Equity (2017 - 2018)

Alterity Therapeutics (ATHE) has 2 years of Common Equity data on record, last reported at $12.2 million in Q2 2018.

  • For Q2 2018, Common Equity fell 31.59% year-over-year to $12.2 million; the TTM value through Jun 2018 reached $12.2 million, down 31.59%, while the annual FY2018 figure was $12.2 million, 31.85% down from the prior year.
  • Common Equity reached $12.2 million in Q2 2018 per ATHE's latest filing, down from $17.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $17.8 million in Q2 2017 and bottomed at $12.2 million in Q2 2018.